Spyre Therapeutics, Inc. — Form 8-K
Filed October 7, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 30/100
What the filing says
Spyre Therapeutics completed an underwritten public offering of 4,117,648 firm shares at $79.90 per share (plus 617,647 optional shares), raising ~$328M gross proceeds. Underwriters: Jefferies, TD Securities, Leerink Partners, Stifel (leads). Closing: October 7, 2026. Lock-up: 60 days on insiders. Net proceeds for R&D and general corporate purposes.
Why this rating
Secondary equity offering of ~$328M is ~30% of $1.1B market cap—meaningful capital raise but standard financing activity for biotech; no M&A, no strategic pivot, routine dilution.
See more from October 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.